No Detail Found!

Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus

Author(s)
Bilal Jawed Department of Pharmacology, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan; Department of Pharmacy, Chiniot General Hospital, Karachi, Pakistan
Shadab Ahmed Department of Pharmacology, Faculty of Pharmacy, University of Karachi,Karachi,Pakistan
Syed Qamar Abbas Department of Pharmacology, Faculty of Pharmacy, University of Karachi,Karachi,Pakistan
Zeeshan Ahmed Department of Pharmacy, Iqra University,Karachi,Pakistan
Shomaiza Andleeb Department of Pharmacy, Iqra University,Karachi,Pakistan
Salman Ashfaq Ahmad Department of Pharmacy, Iqra University,Karachi,Pakistan
Muhammad Asif Iqra University Nursing College, Iqra University,Karachi,Pakistan
Erum Akhter Department of Pharmacy, Chiniot General Hospital,Karachi,Pakistan
Salman Ahmed Department of Pharmaceutics, Faculty of Pharmacy, University of Sindh,Jamshoro,Pakistan
Muhammad Waleed Hussain Department of Pharmacology, Shaheed Benazir Bhutto Dewan University,Karachi,Pakistan
Adnan Iqbal Department of Pharmacology, Faculty of Pharmacy, University of Karachi,Karachi,Pakistan
Azfar Athar Ishaqui Department of Pharmacy, Iqra University,Karachi,Pakistan
Abstract
Diabetes mellitus is a multifaceted metabolic disorder, which often required frequent blood glucose monitoring, poly-pharmacy and timely adjustments for its management. The present study focuses to check the effectiveness of empagliflozin add-on therapy in diabetic patients already taking metformin and glimepiride. This was observational, comparative and follow-up cohort study, conducted in a tertiary care hospital of Pakistan. Ninety subjects were enrolled and evenly distributed in Group A (patients on oral therapy of Metformin & Glimepiride) and Group B (patients on oral therapy of metformin, glimepiride and empagliflozin) randomly. The results showed that the addition of empagliflozin to metformin and glimepiride standard therapy provided better control over blood sugar with a significant decrease in HbA1c (16.1% decrease in HbA1c for Group B patients against 8.2% in Group A patients), FBS (23.8% decrease as compared to 14.6% decrease) and BMI (1.5% decrease in Group B patients against 0.06% increase in Group A). The addition of empagliflozin did not exacerbate the toxicity of the existing regimen and is safe to be included in multiple drug regimens. Empagliflozin addition to standard antidiabetic therapy might possess beneficial impacts in managing poorly controlled Type-2 Diabetes Mellitus in the Pakistani population.
Publication Details
Page(s) 1733-1738
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: 6, Year: 2022

Request the full text from PASTIC

Keywords
Diabetes mellitus, HbA1C, Diabetes mellitus, Metformin, glimepiride, Empagliflozin
0

Citations

0

Downloads

154

Views